menu ☰
menu ˟

AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy

10 Aug 2017
Applied Genetic Technologies Corporation has filed an investigational new drug application with the FDA to begin a phase 1/2 clinical trial of its gene therapy candidate for X-linked retinitis pigmentosa, according to a company press release.X-linked...

Click here to view the full article which appeared in Optometry

IPH Logo